Document is current
Any future updates will be listed below
-
Authors
Song, Edward Z. https://orcid.org/0000-0002-4022-9753
Timpanaro, Andrea
Meechan, Michael https://orcid.org/0000-0003-2710-606X
Elena-Sanchez, Leonel
Li, Lucy Z. https://orcid.org/0000-0003-4616-736X
Jamet, Sophie
Lau, Davina S. https://orcid.org/0009-0005-3744-868X
Winter, Lily I. https://orcid.org/0009-0002-3868-3284
Dun, Matthew D. https://orcid.org/0000-0002-9063-5370
Foster, Jessica B. https://orcid.org/0000-0002-8001-5960
Evans, Myron K.
Pattwell, Siobhan S.
Kalia, Vandana
Sarkar, Surojit
Jensen, Michael C.
Biery, Matthew C. https://orcid.org/0000-0001-6152-3604
Vitanza, Nicholas A. https://orcid.org/0000-0002-3966-4985
- License Information
-
More Information
Article History
Received: 28 March 2025
Accepted: 29 September 2025
First Online: 11 November 2025
Competing interests
: E.Z.S., M.C.J. and N.A.V. are inventors on pending patents related to this study, which are disclosed in U.S. Provisional Patent Application No. 63/569,626, entitled “CXCR3-ENGINEERED ANTI-B7H3 CAR T CELLS”, U.S. Provisional Patent Application No. 63/653,023, entitled “CXCR3 ISOFORMS TO IMPROVE ANTI-B7-H3 RECOMBINANT RECEPTOR TRAFFICKING”, and International Patent Application No. PCT/US2025/021354, entitled “CXCR3 ISOFORMS TO IMPROVE RECOMBINANT RECEPTOR TRAFFICKING”. M.C.J. holds equity in and is the Chief Scientific Officer of BrainChild Bio, Inc. M.C.J. holds equity in, is a Board Observer for and serves as a member of the Joint Steering Committee of Umoja Biopharma, Inc. N.A.V. holds equity in and serves as the Scientific Advisory Board Chair for BrainChild Bio, Inc. All other authors declare no competing interests.
